Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 10:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 246 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Metastatic Prostate Cancer
Interventions
AZD0516, AZD9574
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years · Male only
Enrollment
283 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
11
States / cities
Fayetteville, Arkansas • Los Angeles, California • Towson, Maryland + 8 more
Conditions
Prostate Cancer, Prostate Adenocarcinoma, Prostate Cancer Metastatic, Castration-resistant Prostate Cancer
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Male only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
New York, New York • Durham, North Carolina • Madison, Wisconsin
Conditions
Metastatic Prostate Cancer
Interventions
ORIC-944, Abiraterone acetate (Zytiga®) 250 mg or 500 mg tablets, Apalutamide (Erleada™) 60 mg or 240 mg tablets, Darolutamide (Nubeqa®) 300 mg tablets, Enzalutamide (Xtandi®) 40 mg capsules or 40 mg and 80 mg tablets
Drug
Lead sponsor
ORIC Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
20
States / cities
Colorado Springs, Colorado • Plantation, Florida • Arlington Heights, Illinois + 17 more
Conditions
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer
Interventions
Glycosylated Recombinant Human Interleukin-7, Laboratory Biomarker Analysis
Biological · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
16
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 10 more
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
Radium-223 dichloride (Xofigo, BAY88-8223)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,472 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
49
States / cities
Anchorage, Alaska • Scottsdale, Arizona • Daly City, California + 46 more
Conditions
Advanced Solid Tumors, CRPC, mCRPC, Metastatic Castrate-resistant Prostate Cancer, PT-112, Prostatic Neoplasms, Genital Neoplasms, Male, Urogenital Neoplasms, Neoplasms by Site
Interventions
PT-112 Injection
Drug
Lead sponsor
Promontory Therapeutics Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
17
States / cities
Phoenix, Arizona • Tucson, Arizona • Duarte, California + 14 more
Conditions
Prostate Cancer
Interventions
Pazopanib, Docetaxel, Prednisone, Pegfilgrastim
Drug
Lead sponsor
Daniel George, MD
Other
Eligibility
18 Years and older · Male only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
2
States / cities
Chicago, Illinois • Durham, North Carolina
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
Valemetostat, Darolutamide
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
9
States / cities
La Jolla, California • Boston, Massachusetts • Newton, Massachusetts + 6 more
Conditions
Metastatic Castration-resistant Prostate Cancer, Androgen Resistant Prostatic Cancer
Interventions
VERU-111, Enzalutamide, Abiraterone
Drug
Lead sponsor
Veru Inc.
Industry
Eligibility
18 Years to 100 Years · Male only
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
40
States / cities
Anchorage, Alaska • Tucson, Arizona • Los Angeles, California + 36 more
Conditions
Prostatic Neoplasms
Interventions
Prednisone, sunitinib, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Male only
Enrollment
873 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
87
States / cities
Decatur, Alabama • Huntsville, Alabama • Anaheim, California + 73 more
Terminated Phase 1Phase 2 Interventional Results available

PRO-MERIT (Prostate Cancer Messenger RNA Immunotherapy)

NCT04382898
Conditions
Prostate Cancer
Interventions
BNT112, Cemiplimab
Biological · Drug
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older · Male only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
5
States / cities
Tucson, Arizona • Miami, Florida • Pittsburgh, Pennsylvania + 2 more
Conditions
Metastatic Castration Resistant Prostate Cancer (mCRPC)
Interventions
BAY2315497 Injection, Darolutamide(BAY1841788)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Male only
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
3
States / cities
New Orleans, Louisiana • Omaha, Nebraska • New York, New York
Conditions
Metastatic Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Lymph Nodes, Stage IVB Prostate Cancer AJCC v8
Interventions
Avelumab, Biospecimen Collection, Bone Scan, Computed Tomography, Magnetic Resonance Imaging, Peposertib, Questionnaire Administration, Radium Ra 223 Dichloride
Drug · Procedure · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
32
States / cities
Duarte, California • Los Angeles, California • Orange, California + 24 more
Conditions
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Interventions
INR731, Enzalutamide, Abiraterone, Androgen deprivation therapy (ADT)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Metastatic Castration Resistant Prostate Cancer
Interventions
LAVA-1207, LAVA-1207 plus Pembrolizumab
Biological
Lead sponsor
Lava Therapeutics
Industry
Eligibility
18 Years and older · Male only
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
6
States / cities
San Francisco, California • Minneapolis, Minnesota • St Louis, Missouri + 3 more
Conditions
Prostate Cancer
Interventions
CTT1403, CTT1057, 68Ga-PSMA-11
Drug
Lead sponsor
Cancer Targeted Technology
Industry
Eligibility
18 Years and older · Male only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
San Francisco, California
Conditions
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions
Atezolizumab, Cabozantinib S-malate
Biological · Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older · Male only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Prostatic Neoplasms
Interventions
CC-90011, Abiraterone, Prednisone
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
New York, New York
Conditions
Neoplasms
Interventions
GSK2636771, Enzalutamide
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older · Male only
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
7
States / cities
Duarte, California • Los Angeles, California • Washington D.C., District of Columbia + 3 more
Conditions
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Interventions
Sipuleucel-T
Biological
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Conditions
Metastatic Castration Resistant Prostate Cancer
Interventions
Rucaparib
Drug
Lead sponsor
pharmaand GmbH
Industry
Eligibility
18 Years and older · Male only
Enrollment
277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
58
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 47 more
Conditions
Prostatic Neoplasms
Interventions
Pembrolizumab, Olaparib, Abiraterone acetate, Prednisone, Enzalutamide, Prednisolone
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
793 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
29
States / cities
Fullerton, California • Los Angeles, California • Washington D.C., District of Columbia + 24 more
Conditions
Advanced Metastatic Castration-resistant Prostate Cancer, Prostate Specific Membrane Antigen (PSMA) Expression
Interventions
225Ac-PSMA-Trillium (BAY3563254)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
4
States / cities
Duarte, California • Minneapolis, Minnesota • Omaha, Nebraska + 1 more
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
REGN4336, REGN5678
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
13
States / cities
Palo Alto, California • New Haven, Connecticut • Louisville, Kentucky + 8 more